# GLOW Legal Status, FDA 503A Category, and Compounding Access — GLOW peptide > GLOW legal status, the GLOW peptide blend read against the FDA: its constituents are research peptides in 503A Category 2 today, with an FDA advisory committee scheduled to discuss BPC-157 and TB-500 in July 2026. Present-tense facts. Access is restricted today and under active FDA review. Here is the present-tense FDA picture for each constituent, with the momentum chalked in and nothing assumed about the outcome. ## GLOW legal status, stated present-tense GLOW legal status is best read constituent by constituent, because GLOW is not a single approved drug — it is a non-standardized combination of research peptides, and the strictest constituent status governs how the blend can be accessed. None of GLOW's three peptides is an FDA-approved drug. As compounding ingredients, GHK-Cu (for injectable routes), BPC-157 and TB-500 currently sit in FDA's 503A "Category 2" — bulk drug substances FDA has identified as those that may present significant safety risks — effective with FDA's September 29, 2023 update to the list of nominated substances [13][14]. In plain terms, compounding-pharmacy access to these peptides is restricted right now. The more hopeful and equally factual half of the picture: that status is not frozen. Access is under active FDA review and may expand in 2026. FDA has scheduled a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to discuss several of these peptides as candidates for the 503A bulks list [15]. What follows lays out exactly what is decided, what is merely scheduled, and what no one should treat as settled. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply anything. ## What FDA 503A Category 2 means right now Under the Federal Food, Drug, and Cosmetic Act, compounding is governed by two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [13]. A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than a finished approved drug — only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [13]. FDA's interim policy sorted nominated substances into categories. Category 1 substances are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks, and they are explicitly NOT covered by that enforcement discretion — FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance [13][14]. That is the present-tense reality for GLOW's injectable constituents: their Category 2 placement means routine 503A compounding access is restricted while that status stands. ## The momentum: an FDA advisory committee meeting is scheduled for July 2026 Here is the forward-leaning part, anchored strictly to what FDA has actually published. BPC-157 and TB-500 are on the agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" [15]. An advisory committee taking up a substance is a real step in evaluation — it is how candidates move through the process — and it signals that the question of expanded access is live, not closed. What it is not: a decision. A PCAC discussion is advisory, not a final FDA determination, and inclusion on a final bulks list is decided by FDA rulemaking informed by — but not bound to — the committee [13][15]. No reclassification has occurred, none is dated, and the outcome of the July 2026 meeting is unknown. Reports circulating from commercial and clinic sources of an early-2026 reclassification, or of specific dated removals from Category 2, could not be confirmed from any authoritative FDA source and are not treated as fact here. The accurate statement is the measured one: access is currently restricted, the matter is under active review, and it may expand in 2026 — without anyone knowing how the committee will land. ## One constituent is not on that agenda: injectable GHK-Cu GLOW's regulatory picture splits cleanly here, and the split is worth marking carefully. BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda [15]. Injectable GHK-Cu is not — it does not appear on that agenda, and its injectable form remains in Category 2 [14][15]. So even the momentum that exists applies to two of GLOW's three peptides, not all three. And injectable GHK-Cu must be kept separate from cosmetic copper peptide, which is a different regulatory context entirely. As a topical cosmetic ingredient, the copper tripeptide is named "Copper Tripeptide-1" (INCI) and is regulated under cosmetics rules, which do not require FDA pre-market approval of the ingredient [16]. That topical cosmetic status is genuinely different from the injectable-drug compounding question: FDA identified "GHK-Cu (for injectable routes of administration)" as a Category 2 bulk substance citing immunogenicity-related concerns for injection [14]. The legal copper serum on a shelf and an injectable GHK-Cu bulk substance are not the same regulatory animal, and conflating them is a common error this page avoids. ## How legally compounded peptide access works, in general Setting aside which substances are currently eligible, the lawful pathway for any compounded medication is the same, and it is worth understanding in general terms. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [13]. Telehealth is one valid front-end channel for that evaluation, but it is a route to a licensed-prescriber consultation and prescription, not a separate legal status; it does not expand which substances may be compounded or remove the need for a legitimate clinical evaluation and a valid prescription [13]. If appropriate and lawful, the prescriber issues a valid, patient-specific prescription, which is then dispensed by a state-licensed 503A compounding pharmacy or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [13]. The ingredient-eligibility caveat sits on top of all of it: a compounder may use the requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [13][14]. This page names no specific pharmacy, clinic, telehealth provider or vendor, describes no dosing, and describes no way to obtain a restricted substance outside this framework — it is a map of the landscape, not a route around it. --- A chalkboard reading of the GLOW peptide blend — each constituent's evidence worked through and every blend-level gap chalked in the margin, with no clinic at the board and nothing here dispensed.